Opexa Therapeutics announced that the FDA has granted Tovaxin fast track designation for the treatment of patients with secondary progressive multiple sclerosis (SPMS). Opexa plans to initiate a Phase 2b clinical trial with Tovaxin in SPMS patients in lieu of the fast track designation.
Tovaxin is a personalized cellular immunotherapy treatment, derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.
For more information call (281) 775-0600 or visit www.opexatherapeutics.com.